Abstract: A dental tissue regenerative composition. The composition includes a combination of (1) human dental pulp stem cells and (2) at least one of human umbilical vein endothelial cells or vascular endothelial growth factor. The combination is encapsulated in a light-activated gelatin methacrylate hydrogel.

Abstract: The present invention discloses a non-acidic-candy based composition for arresting or reversing dental caries by transforming the oral cavity from an acidic, bacteria-filled environment to an environment more conducive to remineralization by quickly neutralizing the acids recreated by ingestion of acidic compounds or by cariogenic bacteria while supplying necessary ions for tooth remineralization. This improves oral health, prevents pain and suffering, and serves as a conduit to deliver additional therapeutic agents. The composition comprises any combination of a calcium-based compound, a bicarbonate compound, a fluoride compound, an active ingredient, a therapeutic agent based on need, a non-cariogenic sweetener, a hydrating agent, at least one additive, and water.

Abstract: A nanoparticle composition for oral care includes at least one of a first set of spherical nanoparticles or a second set of coral shaped nanoparticles, and a stabilizing agent. The nanoparticle composition is added to a carrier suitable for application to an oral cavity, including to teeth and surrounding oral tissues. The nanoparticle composition is configured to control the pH of the microenvironment to which it is applied, thereby preventing and/or treating a variety of oral conditions. The nanoparticle composition can be provided as a concentrated nanoparticle additive addable to a mouthwash, mouth rinse, dentifrice, mouth spray, oral gel, denture cleaning solution, or other carrier suitable for oral application.

Abstract: Composition comprising hectorite and pectin The present invention relates to a gel-type composition, preferably a cosmetic composition, comprising at least one pectin and an unmodified hectorite. The invention also relates to a cosmetic process comprising at least one step that consists in applying a composition as defined above to the skin and/or the hair.

Abstract: The invention relates to a thickening composition intended for topical application on the skin, lips or skin appendages, said thickening composition comprising at least one oil derived from a biological source and at least one poly(farnesene) polymer having a number average molar mass ranging from 10,000 to 120,000 g/mol. The invention also relates to a cosmetic composition comprising the thickening composition according to the invention and the use of the thickening composition according to the invention in a cosmetic composition.

Abstract: The invention relates to a cosmetic composition for application in the eye area in the form of a gelatinous emulsion, and to the preparation and use thereof.

Abstract: The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and a water phase, the oil phase comprising at least one membrane-forming substance forming a lamellar membrane in the foam formulation.

Abstract: An oral remineralization accelerating composition includes: a first pH increasing component, sodium bicarbonate, having a concentration in the range from 1 to 10 weight/volume percent, preferably in the subrange from 2 to 5 weight/volume percent; sodium alginate, having a concentration in the range from 0.5 to 5 weight/volume percent; a bacteria saturating component, xylitol, having a concentration in the range from 10 to 80 weight/volume percent, preferably in the subrange from 20 to 40 weight/volume percent; and a critical pH decreasing component, either casein phosphopeptide or sodium fluoride, having a concentration in the range from 0.02 to 5 weight/volume percent, such that the critical pH of tooth structure is reduced to a value below 5.5.

Abstract: The present invention is a formable dental treatment tray utilizing poly(2-ethyl-2-oxazoline) and a gelatinous active. Blending of the active is accomplished by mixing the Poly(2-ethyl-2-oxazoline) with an active ingredient, such as a peroxide like hydrogen peroxide, carbamide peroxide, sodium perborate, or sodium percarbonate, usually also with water or an appropriate organic solvent. Peroxide concentrations in these new gels can reach a 30% concentration of hydrogen peroxide while maintaining a shelf life of six months at room temperature without developing peroxide decomposition. The gels are applied to an appropriate backing and dried to a gelatinous state. In use, the active is hydrated and regains adhesiveness. Then the tray is pressed and formed around a user's dental arch to form the customizable tray. Multiple active ingredients may be used, with or without peroxide, for accomplishing desired treatment regimens.

Abstract: Disclosed are compositions, methods and kits for producing natural, organic personal hygiene and health maintenance products. The products can be produced and regulated under food preparation standards for safety, sterility and efficacy and personalized and prepared for an individual user in consideration of the user's sensitivities, allergies. The compositions, methods and kits are essentially free of chemically-formulated constituents, non-irritating, stable and environmentally friendly properties including organically grown raw materials and biodegradable products.

Abstract: The present invention relates to a combination comprising polyglyceryl-4 caprate and glyceryl monocaprylate, its use as emollient and/or cleansing agent and to the resulting cosmetic compositions.

Abstract: An orally administered, imbibed, or ingested consumer product, which can ordinarily impart a salty taste and/or after taste to the mouth due to the presence of one or more salts, wherein the salty taste and/or aftertaste is reduced or inhibited by the presence of one or more cooling materials. Related methods of reducing or inhibiting the salty taste and/or aftertaste ordinarily imparted by an orally administered, imbibed, or ingested consumer product to the mouth of the end user are also described.

Abstract: The present invention relates to compounds, compositions, and methods for modulating skin pigmentation and treating or preventing UV-induced skin damage, erythema, aging of the skin, sunburn, and hyperpigmentation in a subject. The compounds, compositions, and methods of the present invention generally involve Malassezia-derived compounds, including malassezin and indirubin, and/or chemical analogs thereof. Other applications of the compounds and compositions disclosed herein include, but are not limited to, improving hyperpigmentation caused by a hyperpigmentation disorder, inducing melanocyte apoptosis, and modulating arylhydrocarbon receptor (AhR) activity, melanogenesis, melanin production, melanosome biogenesis, melanosome transfer, melanocyte activity, and melanin concentration.

Abstract: A composition for application to the skin or other substrate, which acts in conjunction with any perfume product, to extend the longevity of a fragrance, compared to the perfume in the absence of the composition. In particular, the composition contains a musk substance and at least 50% of a non-scented, viscous, low-volatility, solvent for perfume ingredients.

Abstract: The purpose of the present invention is to provide: a cosmetic base material which is capable of stably retaining lecithin in the form of a liposome; and a cosmetic preparation which contains this base material and has excellent usability (such as soft texture when applied to the skin and quick adhesion to the skin) and excellent stability. The present invention relates to: a cosmetic base material which is characterized by containing (a) a liposome that contains (a-1) lecithin and (a-2) an oryzanol, and (b) an aqueous medium that contains (b-1) water and (b-2) a polyhydric alcohol, and which is also characterized in that the ratio of the blending amount of the liposome (a) to the blending amount of the aqueous medium (b), namely (a):(b) is within the range of from 1:99 to 1:32; and a cosmetic preparation which contains a microemulsion part and a liposome part that is composed of this base material.

Abstract: The present invention relates to acetylcholine receptor inhibitory peptides and uses thereof, wherein phages with high binding affinity for acetylcholine receptors were screened using a random peptide recombinant phage, and acetylcholine receptor-binding peptides were selected through DNA of the phages. By having confirmed, using the selected peptides, the binding affinity for acetylcholine receptors and the effect of inhibiting the action of acetylcholine receptors, and having confirmed, via the modifications of the peptides, peptide sites and sequences that are vital in binding to acetylcholine receptors, the acetylcholine receptor inhibitory peptides of the present invention are expected to be used in the development of a cosmetic composition for alleviating wrinkles, a medicine for the prevention or treatment of acetylcholine receptor-associated diseases, and a health functional food for the amelioration thereof.

Abstract: Provided are pharmaceutical compositions for skin lightening, which are particularly useful in treating skin hyperpigmentation, together with methods for their use. The compositions comprise a peptide having a sequence comprising PKEK, alpha arbutin and/or sutilains.

Abstract: Disclosed is an encapsulated composition comprising at least one perfume and/or cosmetic ingredient that is entrapped in a matrix. The matrix comprises a starch and a hemicellulose.

Abstract: The present invention features cosmetic compositions and a method for pigmentations that create realistic and long-wearing freckles on a user's skin. These compositions include advantages such as being applicable to various skin types. Other advantages include resistance to smearing and a more realistic appearance superior to alternative faux freckle solutions. These compositions can also be applied using various apparatuses.

Abstract: Provided are dermal barrier compositions that create a barrier between external irritants or coverings and the skin of a subject upon which the composition is applied. A dermal barrier composition as provided herein includes hydrophilic polymer or copolymer and a fatty acid-amino acid conjugate. Also provided are methods of producing a dermal barrier composition. Also provided are methods of using a dermal barrier composition to maintain makeup on the skin of a subject.

Abstract: A transparent thickening blend for use in personal care formulations is provided having 1 to 10 wt %, based on weight of the transparent thickening blend, of a carbohydrate-based gelling agent; 0 to 79 wt %, based on weight of the transparent thickening blend, of a polar oil; 20 to 99 wt %, based on weight of the transparent thickening blend, of a short chain silanol having structure (I) wherein n is an average of 1 to 40; and 0 to 30 wt %, based on weight of the transparent thickening blend, of an organo modified silicone.

Abstract: A solid soap containing, (A) 77 to 91 mass % of an alkali metal salt of a saturated fatty acid having an even number of carbon atoms from 12 to 18, (B) 0.005 to 1 mass % of an alkali metal salt of a saturated fatty acid having an odd number of carbon atoms from 13 to 17, (C) 0.5 to 5 mass % of glycerol, and (D) 5 to 18 mass % of water.

Abstract: The present invention provides a hair care composition comprising 2.5 fl. oz. 99% hemp oil; 2 fl. oz. 2% minoxidil; 2.5 fl. oz. 99% tea tree oil; 2.5 fl. oz. 99% peppermint oil; and 2 fl. oz. placenta. A hair care system may comprise a spray bottle; and a predetermined quantity of the hair care composition. A method for treating a user's hair may include the following steps: wash and dry a user's hair; apply a predetermined quantity of the hair care composition to the user's hair; massage the hair care composition thoroughly into the user's hair and leave the hair care composition in the user's hair.

Abstract: A topical composition for treating fungal skin infections with associated inflammation may include making or administering to the affected skin area an antifungal and steroid, such as a corticosteroid. Certain compositions may include antifungals such as itraconazole or econazole and corticosteroids such as fluticasone, fluocinonide, or clobetasol. The antifungal and steroid may be within a cream. In one example, a commercially available econazole nitrate cream may be used in conjunction with a commercially available fluocinonide cream or commercially available clobetasol cream to treat the affected skin area.

Abstract: Described herein are transdermal formulations and methods of using the same.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: Provided herein are nasal spray formulations including a compound of formula (I) and methods of using these nasal spray formulations for the treatment of ADHD, or a cognitive dysfunction disease or disorder in a subject having a neurofibromatosis. In some embodiments, the neurofibromatosis is neurofibromatosis type-1, neurofibromatosis type-2, or schwannomatosis. Compounds of formula (I) are represented by wherein R1, R2, R2a, R3, R3a, and R3b are as defined and described herein.

Abstract: The present invention relates to a polymer composite for controlled release of an agent. In particular, the present invention relates to a stimuli-responsive polymer composite that can provide for controlled release of an agent in response to light. The polymer composite may be particularly suitable for the controlled delivery of a drug that is modulated by light.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: A method for manufacturing an orally disintegrating tablet, in which adequate hardness for preventing breakage of the tablet during transport or handling by a medical practitioner or a patient is provided while rapid disintegration is maintained. The method for manufacturing an orally disintegrating tablet according to an embodiment of the present invention comprises spraying or dropping a liquid including hydroxypropyl cellulose having a viscosity in a 2% aqueous solution at 20° C. of 150 mPa·s or more and 400 mPa·s on additives, and performing fluid bed granulation. The liquid including hydroxypropyl cellulose may be sprayed or dropped on the additives so that the content of the hydroxypropyl cellulose with respect to 100 wt % of the orally disintegrating tablet is 0.2 wt % to 5 wt %.

Abstract: The present disclosure relates generally to compositions and methods for improving gastrointestinal absorption function and correct deficiencies by preserving intestinal epithelial absorptive function. In particular, the compositions and methods for useful for improving gastrointestinal absorption of electrolytes.

Abstract: Provided is a method of encapsulation, the method including: providing a first mixture; applying heat to the first mixture until the first mixture reaches a first temperature; providing a second mixture; applying heat to the second mixture until the second mixture reaches a second temperature; mixing the first mixture with the second mixture to obtain a third mixture; providing a fourth mixture; applying heat to the fourth mixture until the fourth mixture reaches a third temperature; mixing the third mixture with the fourth mixture to obtain a fifth mixture.

Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.

Abstract: Disclosed are simple yet stable and effective compositions comprising from about 1% to about 5% by weight of the composition of a minocycline or mixtures thereof and pharmaceutically acceptable ingredients comprising from about 60% to about 99% by weight of the composition of at least one hydrophobic oil, and from about 5% to about 25% by weight of the composition of at least one fatty alcohol, wherein the at least one hydrophobic oil and the at least one fatty alcohol are sufficient to ensure the pharmaceutically acceptable assay stability of the minocycline in the composition under 3 months accelerated stability conditions at 40° C./75% RH. Also disclosed are methods of treatment of acne, rosacea and impetigo.

Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

Abstract: The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.

Abstract: The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.

Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: The present invention relates to pharmaceutical composition, comprising certain phosphate binder particles having a certain particle size distribution, a process for the manufacture of the pharmaceutical composition and the use of sucroferric oxyhydroxide having a certain particle size distribution for the manufacture of a pharmaceutical composition.

Abstract: Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bile acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H2-receptor antagonists, y-aminobutyric acid-I3 (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

Abstract: The present invention relates to a nanohelix-substrate complex for controlling adhesion and polarization of macrophages, a manufacturing method thereof, and a method of controlling adhesion and polarization of macrophages by using the nanohelix-substrate complex, and the method of controlling adhesion and polarization of macrophages may temporally and reversibly control adhesion and phenotypic polarization of macrophages in vivo and ex vivo by controlling application/non-application of a magnetic field to the nanohelix-substrate complex.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: Disclosed are nanoparticle compositions and methods for treating cancer in a subject in need thereof. The nanoparticle compositions and methods may be utilized to treat cancers in a subject that are characterized by susceptibility to synthetic lethality via administering a combination of agents that induce synthetic lethality.

Abstract: Anti-tumor platinum drug mineralized protein nanoparticles and a preparation method therefor are disclosed. The anti-tumor platinum-based drug mineralized protein nanoparticles include a platinum drug and a protein. The protein is one or more selected from the group consisting of albumin, transferrin, hemoglobin, and low-density lipoprotein. The platinum drug is cisplatin, iodoplatin, bromoplatin, oxaliplatin, carboplatin, or nedaplatin. A drug loading of the anti-tumor platinum-based drug mineralized protein nanoparticles is 1% to 50%.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles.

Abstract: The invention relates to a transdermal therapeutic system that includes a) a backing layer which faces away from the skin, is impermeable to the active substance, and is equipped with an adhesive layer for fixing onto the skin, b) an active substance reservoir which contains at least one active substance, c) a barrier layer which faces the skin, adjoins the active substance reservoir, is impermeable to the active substance and has at least one opening, and d) a removable protective layer, in which the backing layer which is equipped with the adhesive layer projects beyond the barrier layer on all sides.